Compare AVTR & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVTR | ABVX |
|---|---|---|
| Founded | 1904 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 9.0B |
| IPO Year | 2019 | N/A |
| Metric | AVTR | ABVX |
|---|---|---|
| Price | $11.47 | $134.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $14.86 | ★ $115.83 |
| AVG Volume (30 Days) | ★ 9.4M | 1.9M |
| Earning Date | 02-06-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,575,200,000.00 | $6,231,374.00 |
| Revenue This Year | N/A | $6.80 |
| Revenue Next Year | $0.05 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.62 | $4.77 |
| 52 Week High | $23.32 | $148.83 |
| Indicator | AVTR | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 51.23 | 57.38 |
| Support Level | $11.08 | $139.42 |
| Resistance Level | $11.53 | $147.00 |
| Average True Range (ATR) | 0.31 | 7.25 |
| MACD | 0.08 | 0.98 |
| Stochastic Oscillator | 81.02 | 63.38 |
Avantor Inc provider of products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. The company has three geographic segments: the Americas, Europe, and AMEA. The company's product group consists of Equipment & instrumentation, Services & specialty procurement, Proprietary materials & consumables, and Third-party materials & consumables. Materials & consumables include high-purity chemicals and reagents, lab products and supplies, specialized formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, and education and microbiology and clinical trial kits, peristaltic pumps and fluid handling tips.
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.